Serina Therapeutics Provides Update on SER-252 Development
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a biotechnology firm focusing on innovative drug optimization technologies, has recently introduced key updates on its SER-252 program designed for advanced Parkinson's disease. The U.S. Food and Drug Administration (FDA) has placed the Company’s Investigational New Drug (IND) application on clinical hold as it requests additional information related to specific components in the formulation. It is essential to note that the FDA's feedback pertains only to a common excipient and not the active drug itself or its mechanism of action.
Regulatory Actions and Next Steps
Moving forward, Serina plans to collaborate closely with the FDA to ensure all concerns are promptly addressed. The company anticipates formally receiving the clinical hold letter from the FDA within the next few weeks. In previous discussions, the FDA expressed support for Serina's development approach for SER-252 under the 505(b)(2) New Drug Application pathway, a route that offers a streamlined process for certain applications.
CEO’s Commitment to the Program
Steve Ledger, the Chief Executive Officer of Serina, expressed his appreciation for the FDA’s constructive engagement, stating, "We will provide the additional information requested promptly as we continue to move forward in the registrational trial for SER-252. Importantly, the feedback does not relate to the underlying drug candidate or its intended mechanism, and we continue to believe strongly in the potential of SER-252 to improve treatment options for people living with advanced Parkinson's disease.”
Support and Confidence from Leadership
Greg Bailey, MD, a Board Member of Serina and Executive Chairman of Juvenescence, reiterated his commitment to Serina, indicating his support extends both financially and strategically. He emphasized that receiving regulatory feedback is a normal part of responsible drug development and expressed confidence in the team’s ability to address the FDA’s comments. The leadership confidence remains robust regarding the long-term potential for SER-252 to enhance the lives of those affected by Parkinson's disease.
Continued Innovation with the POZ Platform
In addition to SER-252, Serina remains dedicated to advancing its broader pipeline based on the proprietary POZ Platform technology. This includes SER-270, a once-weekly injectable treatment aimed at tardive dyskinesia (TD), along with other innovations in their POZ-LNP, POZ-ADC, and POZ-AOC technology. These platforms are designed to enhance drug efficacy and patient experience across a variety of therapeutic applications.
Study Design Overview for SER-252
The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b clinical trial comprising both single and multiple ascending dose components, which will include 40 participants in their initial phase. This trial aims to assess safety, tolerability, and pharmacokinetics for subcutaneous SER-252 versus placebo while measuring efficacy through various motor functionality assessments.
Understanding SER-252 and Its Mechanism
SER-252 is an investigational therapy based on apomorphine, leveraging the capacity of the POZ platform to deliver consistent dopaminergic stimulation through easy-to-administer subcutaneous injections. The innovative design aims to manage motor fluctuations effectively, particularly for advanced Parkinson's patients, thus improving their daily living and reducing off-time and related complications.
What Sets the POZ Platform Apart
Serina’s POZ technology utilizes a synthetic water-soluble polymer, facilitating more accurate drug loading and release rates during subcutaneous administration. The approach aims to lower adverse effects associated with peak-trough variations in medication levels, enhancing patient outcomes significantly. This advanced drug delivery technology holds promise for broader applications beyond current indications.
About Serina Therapeutics
Serina is at the forefront of biotechnological innovation, dedicated to developing a robust pipeline of therapies targeting various neurological conditions and other health challenges. Located in Huntsville, Alabama, Serina the POZ Platform to enhance the efficacy and safety profiles of multiple therapeutic modalities—including small molecules and antibody-drug conjugates—showcases its commitment to improving patient care. For more details on Serina’s work and innovations, visit their official website.
Frequently Asked Questions
What was the FDA's recent action regarding SER-252?
The FDA placed a clinical hold on SER-252's IND application, requesting additional information about a formulation component.
How does SER-252 aim to help Parkinson’s disease patients?
SER-252 is designed to provide continuous dopaminergic stimulation, helping to manage motor fluctuations and improve daily living for Parkinson's patients.
Who is leading Serina Therapeutics?
Steve Ledger serves as the Chief Executive Officer, guiding the company’s strategic direction and initiatives.
What is the POZ Platform?
Serina's POZ Platform is drug optimization technology focusing on precision in drug delivery to enhance therapeutic efficacy and minimize side effects.
What are the next steps for Serina regarding FDA feedback?
Serina intends to collaborate proactively with the FDA to address the feedback and align on the next steps for the clinical program.
